Search research articles
Contact Us
Filters
Showing results (11-20 of 26) with videos related to
Page
of 3
Sort By:
BMC Urology
|
February 5, 2021
A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance
Samuel W D Merriel, Daniel Moon, Phil Dundee, et al.
Urology
|
February 22, 2023
IsoPSA Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the IsoPSA Validation Study
Jason M Scovell, Mark Stovsky, Alan Partin, et al.
Proteomics. Clinical Applications
|
December 8, 2010
An experimental strategy for quantitative analysis of the humoral immune response to prostate cancer antigens using natural protein microarrays
Sara Forrester, Ji Qiu, Leslie Mangold, et al.
European Urology
|
September 22, 2018
A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy
James McKiernan, Michael J Donovan, Eric Margolis, et al.
Oncotarget
|
February 2, 2017
Promoter methylation of MCAM, ERα and ERβ in serum of early stage prostate cancer patients
Mariana Brait, Mithu Banerjee, Leonel Maldonado, et al.
The Journal of Urology
|
February 28, 2019
Clinical Validation of IsoPSA™, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer
Mark Stovsky, Eric A Klein, Arnon Chait, et al.
The Canadian Journal of Urology
|
February 18, 2020
Assessment of high-grade prostate cancer risk using prostate cancer biomarkers
Whitney N Stanton, E David Crawford, Paul B Arangua, et al.
JAMA Oncology
|
April 1, 2016
A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy
James McKiernan, Michael J Donovan, Vince O'Neill, et al.
Cancer
|
December 11, 2014
Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?
Zachary Klaassen, Abhay A Singh, Lauren E Howard, et al.
Theranostics
|
November 18, 2020
Urinary glycoproteins associated with aggressive prostate cancer
Mingming Dong, T Mamie Lih, Shao-Yung Chen, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 26) with videos related to
Sort By:
Page
of 3
BMC Urology
|
February 5, 2021
A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance
Samuel W D Merriel, Daniel Moon, Phil Dundee, et al.
Urology
|
February 22, 2023
IsoPSA Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the IsoPSA Validation Study
Jason M Scovell, Mark Stovsky, Alan Partin, et al.
Proteomics. Clinical Applications
|
December 8, 2010
An experimental strategy for quantitative analysis of the humoral immune response to prostate cancer antigens using natural protein microarrays
Sara Forrester, Ji Qiu, Leslie Mangold, et al.
European Urology
|
September 22, 2018
A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy
James McKiernan, Michael J Donovan, Eric Margolis, et al.
Oncotarget
|
February 2, 2017
Promoter methylation of MCAM, ERα and ERβ in serum of early stage prostate cancer patients
Mariana Brait, Mithu Banerjee, Leonel Maldonado, et al.
The Journal of Urology
|
February 28, 2019
Clinical Validation of IsoPSA™, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer
Mark Stovsky, Eric A Klein, Arnon Chait, et al.
The Canadian Journal of Urology
|
February 18, 2020
Assessment of high-grade prostate cancer risk using prostate cancer biomarkers
Whitney N Stanton, E David Crawford, Paul B Arangua, et al.
JAMA Oncology
|
April 1, 2016
A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy
James McKiernan, Michael J Donovan, Vince O'Neill, et al.
Cancer
|
December 11, 2014
Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?
Zachary Klaassen, Abhay A Singh, Lauren E Howard, et al.
Theranostics
|
November 18, 2020
Urinary glycoproteins associated with aggressive prostate cancer
Mingming Dong, T Mamie Lih, Shao-Yung Chen, et al.
Page
of 3